Centivax Raises $45M to Commercialize First Universal Flu Vaccine
What You Should Know:
– Centivax, a biotech company developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4,…
Continue Reading